Researchers have identified RUVBL2 as a promising therapeutic target for mitigating post-operative delirium (POD), a condition that significantly exacerbates cognitive decline in older adults. In a rat model of mild cognitive impairment, silencing RUVBL2 post-surgery led to improved cognitive outcomes, indicating its critical role in the metabolic changes induced by surgical stress. The study highlights that surgery triggers metabolic reprogramming in the hippocampus, characterized by increased stress granule formation and altered microglial activity, which are linked to long-term cognitive impairments.

The significance of this work lies in its potential to address a prevalent issue in geriatric medicine. Approximately 25% of older adults experience delirium after surgery, with rates rising to 50% for high-risk procedures. This condition not only prolongs hospital stays but also triples mortality risk and is associated with a rapid progression to Alzheimer’s disease in patients with pre-existing cognitive impairments. By elucidating the role of RUVBL2 in the inflammatory response and metabolic shifts following anesthesia, the study opens avenues for novel interventions that could significantly improve post-operative care for older patients.

The implications of targeting RUVBL2 extend beyond immediate cognitive outcomes. This research may shift current paradigms in drug development for POD, emphasizing the need for therapies that modulate microglial function and metabolic pathways rather than solely focusing on symptomatic relief. If successful, future therapies derived from this research could transform surgical protocols, making them safer for older adults and potentially reducing the incidence of long-term cognitive decline associated with surgical interventions.

Source: lifespan.io